Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Researcher

Irina Lambertz

36 Results

2021

Microbes exploit death-induced nutrient release by gut epithelial cells

Christopher AndersonChristopher B. MedinaBrady J. BarronLaura KarvelyteTania Love AaesIrina LambertzJustin S. A. PerryParul MehrotraAmanda GonçalvesKelly LemeireGillian BlanckeVanessa AndriesFarzaneh GhazaviArne MartensGeert van LooLars VereeckePeter VandenabeeleKodi Ravichandran

A1 Journal Article in NATURE

2020

The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness

Liselot MusIrina LambertzShana ClaeysCandy KumpsWouter Van LoockeChristophe Van NesteGanesh UmapathyMarica VaapilChristoph BartenhagenGenevieve LaureysOlivier De WeverDaniel BexellMatthias FischerBengt HallbergJohannes SchulteBram De WildeKaat DurinckGeertrui DeneckerKatleen De PreterFranki Speleman

A1 Journal Article in SCIENTIFIC REPORTS

2018

Expressed repetitive elements are broadly applicable reference targets for normalization of reverse transcription-qPCR data in mice

Marjolijn RenardSuzanne VanhauwaertMarine VanhomwegenAli RihaniNiels VandammeSteven GoossensGeert BerxPieter Van VlierbergheJody J HaighBieke DecaestekerJolien Van LaereIrina LambertzFranki SpelemanJo VandesompeleAndy Willaert

A1 Journal Article in SCIENTIFIC REPORTS

2017

HBP1 is a negative epigenetic regulator of MYCN-driven neuroblastoma through interaction with the PRC2 complex

Shana ClaeysGeertrui DeneckerIrina LambertzEls JanssensSuzanne VanhauwaertBieke DecaestekerTom Van MaerkenBram De WildeGenevieve LaureysKristina AlthoffJohannes SchulteJean-Baptiste DemoulinLaurel Bate-EyaJan MolenaarFrank WestermannKatleen De PreterFranki Speleman

The ETV5 oncogene is a target of activated ALK signaling in neuroblastoma

Liselot MusIrina LambertzCandy KumpsShana ClaeysGeertrui DeneckerWouter Van LoockeChristophe Van NesteJan KosterRogier VersteegNadine Van RoyBram De WildeGenevieve LaureysJohannes SchulteOlivier De WeverKatleen De PreterFranki Speleman

The ETV5 oncogene is a target of activated ALK signaling in neuroblastoma

Liselot MusIrina LambertzCandy KumpsShana ClaeysGeertrui DeneckerWouter Van LoockeChristophe Van NesteJan KosterRogier VersteegNadine Van RoyBram De WildeGenevieve LaureysJohannes SchulteOlivier De WeverKatleen De PreterFranki Speleman

The ETV5 oncogene is a target of activated ALK signaling in neuroblastoma

Liselot MusIrina LambertzCandy KumpsShana ClaeysGeertrui DeneckerWouter Van LoockeChristophe Van NesteJan KosterRogier VersteegNadine Van RoyBram De WildeGenevieve LaureysJohannes SchulteOlivier De WeverKatleen De PreterFranki Speleman

The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex

Geertrui DeneckerShana ClaeysIrina LambertzEls JanssensSuzanne VanhauwaertBieke DecaestekerTom Van MaerkenBram De WildeGenevieve LaureysKristina AlthoffJohannes SchulteJean-Baptiste DemoulinStephen S RobertsLaurel Bate-EyaJan J MolenaarFrank WestermannKatleen De PreterFranki Speleman

The HBP1 tumour suppressor is a negative epigenetic regulator of MYCN-driven neuroblastoma through interaction with the PRC2 complex

Shana ClaeysGeertrui DeneckerBieke DecaestekerEls JanssensCandy KumpsSara De BrouwerIrina LambertzAnnelies FieuwSuzanne VanhauwaertKristina AlthoffLaurel Bate-EyaEmmy DolmanCaroline WigerupDaniel BexellSven PahlmanKO HenrichLea WehrmannMD HogartyJean-Baptiste DemoulinTom Van MaerkenGenevieve LaureysChristophe Van NesteBram De WildeKaat DurinckFrank WestermannJohannes SchulteKatleen De PreterFranki Speleman

2016

Dual targeting of ALK and RET: establishing a novel basis for the treatment of neuroblastoma

Liselot MusShana ClaeysBram De WildeGenevieve LaureysAlan Van GoethemJohannes SchulteKatleen De PreterIrina LambertzFranki Speleman

Dual targeting of ALK and RET: establishing a novel basis for the treatment of neuroblastoma

Liselot MusShana ClaeysBram De WildeGenevieve LaureysAlan Van GoethemJohannes SchulteKatleen De PreterIrina LambertzFranki Speleman

ETV5 functionally connect ALK and CXCR4 signaling in neuroblastoma

Irina LambertzShana ClaeysCandy KumpsLiselot MusEls JanssensNadine Van RoyBram De WildeGenevieve LaureysJan CoolsOlivier De WeverJohannes SchulteKatleen De PreterFranki Speleman

ETV5 functionally connects ALK and CXCR4 signaling in neuroblastoma

Irina LambertzLiselot MusCandy KumpsShana ClaeysNadine Van RoyBram De WildeGenevieve LaureysJohannes ShulteOlivier De WeverKatleen De PreterFranki Speleman

Sensing mutant ALK: Capicua and ETV5 as executors of aberrant ALK-driven MAPK signaling

Irina LambertzLiselot MusCandy KumpsShana ClaeysWouter Van LoockeChristophe Van NesteJan KosterRogier VersteegNadine Van RoyBram De WildeGenevieve LaureysJohannes SchulteOlivier De WeverKatleen De PreterFranki Speleman

The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex

Shana ClaeysIrina LambertzEls JanssensSuzanne VanhauwaertBieke DecaestekerCandy KumpsSara De BrouwerAnnelies FieuwTom Van MaerkenBram De WildeGenevieve LaureysKristina AlthoffJohannes SchulteLaurel Bate-eyaJan MolenaarJean-Baptiste DemoulinThomas LookKatleen De PreterFranki Speleman

The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex

Shana ClaeysIrina LambertzEls JanssensSuzanne VanhauwaertBieke DecaestekerCandy KumpsSara De BrouwerAnnelies FieuwTom Van MaerkenBram De WildeGenevieve LaureysKristina AlthoffJohannes SchulteLaurel Bate-EyaJan MolenaarJean-Baptiste DemoulinThomas LookKatleen De PreterFranki Speleman

The HBP1 tumor suppressor is an epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex

Shana ClaeysIrina LambertzAlan Van GoethemCandy KumpsSara De BrouwerAnnelies FieuwTom Van MaerkenKristina AlthoffJohannes SchulteJean-Baptiste DemoulinKatleen De PreterFranki Speleman

2015

ETV5 functionally connect ALK and RET signaling in neuroblastoma

Irina LambertzShana ClaeysCandy KumpsLiselot MusAnneleen BeckersEls JanssensNadine Van RoyGenevieve LaureysJohannes SchulteOlivier De WeverKatleen De PreterFranki Speleman

HBP1 downregulation through mutant ALK represents a novel mechanism for cooperative MYCN activation in neuroblastoma

Shana ClaeysIrina LambertzAlan Van GoethemCandy KumpsSara De BrouwerAnnelies FieuwTom Van MaerkenKristina AlthoffJohannes SchulteJean-Baptiste Demoulinthe Neuroblastoma Research ConsortiumKatleen De PreterFranki Speleman

Synergistic combined molecular treatment targeting the HBP1 tumor suppressor gene in neuroblastoma

Shana ClaeysIrina LambertzAlan Van GoethemAnneleen BeckersCandy KumpsTom Van MaerkenJohannes SchulteKatleen De PreterFranki Speleman

The HBP1 tumour suppressor at multiple regulatory cross roads in neuroblastoma

Shana ClaeysIrina LambertzAlan Van GoethemAnneleen BeckersCandy KumpsTom Van MaerkenJohannes SchulteKatleen De PreterFranki Speleman

Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment

Irina LambertzCandy KumpsShana ClaeysSven LindnerAnneleen BeckersEls JanssensDaniel CarterAlex CazesBelamy CheungMarilena De MarianoDavid Camacho-TrujilloAn De BondtSara De BrouwerJay GibbonsIsabel Janoueix-LeroseyGenevieve LaureysChris LiangGlenn MarshallMichael PorcuJunko TakitaIlse Van Den WyngaertNadine Van RoyAlan Van GoethemTom Van MaerkenPiotr ZabrockiJan CoolsJohannes SchulteJorge VialardFranki SpelemanKatleen De Preter

Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment

Irina LambertzCandy KumpsShana ClaeysSven LindnerAnneleen BeckersEls JanssensDaniel CarterAlex CazesBelamy CheungMarilena De MarianoDavid Camacho-TrujilloAn De BondtSara De BrouwerJay GibbonsIsabel Janoueix-LeroseyGenevieve LaureysChris LiangGlenn MarshallMichael PorcuJunko TakitaIlse Van Den WyngaertNadine Van RoyAlan Van GoethemTom Van MaerkenPiotr ZabrockiJan CoolsJohannes SchulteJorge VialardFranki SpelemanKatleen De Preter

Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment

Irina LambertzCandy KumpsShana ClaeysSven LindnerAnneleen BeckersEls JanssensDaniel R CarterAlex CazesBelamy B CheungMarilena De MarianoAn De BondtSara De BrouwerOlivier DelattreJay GibbonsIsabelle Janoueix-LeroseyGenevieve LaureysChris LiangGlenn M MarshallMichael PorcuJunko TakitaDavid Camacho-TrujilloIlse Van Den WyngaertNadine Van RoyAlan Van GoethemTom Van MaerkenPiotr ZabrockiJan CoolsJohannes H SchulteJorge VialardFranki SpelemanKatleen De Preter

A1 Journal Article in CLINICAL CANCER RESEARCH

Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment

Irina LambertzCandy KumpsShana ClaeysSven LindnerAnneleen BeckersEls JanssensDaniel CarterAlex CazesBelamy CheungMarilena De MarianoDavid Camacho-TrujilloAn De BondtSara De BrouwerJay GibbonsIsabel Janoueix-LeroseyGenevieve LaureysChris LiangGlenn MarshallMichael PorcuJunko TakitaIlse Van Den WyngaertNadine Van RoyAlan Van GoethemTom Van MaerkenPiotr ZabrockiJan CoolsJohannes SchulteJorge VialardFranki SpelemanKatleen De Preter

2014

Characterization of ALK driven molecular networks identifies perturbed RET and cholinergic signaling in neuroblastoma

Irina LambertzCandy KumpsShana ClaeysSven LindlerAnneleen BeckersEls JanssensMarilena De MarianoSara De BrouwerJay GibbonsGenevieve LaureysMichael PorcuAlan Van GoethemTom Van MaerkenNadine Van RoyPiotr ZabrockiJan CoolsJohannes SchulteJorge VialardFranki SpelemanKatleen De Preter

The HBP1 tumor suppressor is a druggable ALK downregulated gene controlling MYCN activity

Shana ClaeysCandy KumpsIrina LambertzSara De BrouwerSven LindnerAlan Van GoethemTom Van MaerkenJorge VialardJan CoolsJohannes SchulteKatleen De PreterFranki Speleman

The HBP1 tumor suppressor is a druggable ALK downregulated gene controlling MYCN activity

Shana ClaeysCandy KumpsIrina LambertzSara De BrouwerSven LindnerAlan Van GoethemTom Van MaerkenJorge VialardJan CoolsJohannes SchulteKatleen De PreterFranki Speleman

2013

The need for transparency and good practices in the qPCR literature

Stephen A BustinVladimir BenesJeremy GarsonJan HellemansJim HuggettMikael KubistaReinhold MuellerTania NolanMichael W PfafflGregory ShipleyCarl T WittwerPeter SchjerlingPhilip J DayMónica AbreuBegoña AguadoJean-François BeaulieuAnneleen BeckersSarah BogaertJohn A BrowneFernando Carrasco-RamiroLiesbeth CeelenKate CiborowskiPieter CornillieStephanie CoulonAnn CuypersSara De BrouwerLeentje De CeuninckJurgen De CraeneHélène De NaeyerWard De SpiegelaereKato DeckersAnnelies DheedeneKaat DurinckMargarida Ferreira-TeixeiraAnnelies FieuwJack M GallupSandra Gonzalo-FloresKaren GoossensFemke HeindryckxElizabeth HerringHans HoenickaLaura IcardiRolf JaggiFarzad JavadMichail KarampeliasFrederick KibengeMolly KibengeCandy KumpsIrina LambertzTim LammensAmelia MarkeyPeter MessiaenEvelien MetsSofia MoraisAlberto Mudarra-RubioJustine NakiwalaHilde NelisPal A OlsvikClaudina Perez NovoMichelle PlusquinTony RemansAli RihaniPaulo Rodrigues-SantosPieter RondouRebecca SandersKatharina Schmidt-BleekKerstin SkovgaardKaren SmeetsLaura TaberaStefan ToegelTim Van AckerWim Van Den BroeckJoni Van der MeulenMireille Van GeleGert Van PeerMario Van PouckeNadine Van RoySarah VergultJoris WaumanMarina Tshuikina-WiklanderErik WillemsSara ZaccaraFjoralba ZekaJo Vandesompele

A1 Journal Article in NATURE METHODS

2012

Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma

Sara De BrouwerPieter MestdaghIrina LambertzFilip PattynAnne De PaepeFrank WestermannChristina SchroederJohannes H SchulteAlexander SchrammKatleen De PreterJo VandesompeleFranki Speleman

A1 Journal Article in INTERNATIONAL JOURNAL OF CANCER

Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation

David NittnerIrina LambertzFrederic ClermontPieter MestdaghCorinna KöhlerSøren Jensby NielsenAart JochemsenFranki SpelemanJo VandesompeleMichael A DyerAlexander SchrammJohannes H SchulteJean-Christophe Marine

A1 Journal Article in NATURE CELL BIOLOGY

2011

MicroRNA control of cancer development

Irina LambertzJean-Christophe Marine

2010

An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity

Jessica WynendaeleAnja BöhnkeEleonora LeucciSøren Jensby NielsenIrina LambertzStefanie HammerNadja SbrzesnyDana KubitzaAnja WolfElise GradhandKatharina BalschunIoana BraicuJalid SehouliSilvia Darb-EsfahaniCarsten DenkertChristoph ThomssenSteffen HauptmannAnders LundJean-Christophe MarineFrank Bartel

A1 Journal Article in CANCER RESEARCH

Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis in vivo

Irina LambertzDavid NittnerPieter MestdaghGeertrui DeneckerJo VandesompeleMA DyerJean-Christophe Marine

A1 Journal Article in CELL DEATH AND DIFFERENTIATION

2009

Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53

Tom Van MaerkenLiesbeth FerdinandeJasmien TaildemanIrina LambertzNurten YigitLiesbeth VercruysseAli RihaniMartin MichaelisJindrich CinatlClaude CuvelierJean-Christophe MarineAnne De PaepeMarc BrackeFranki SpelemanJo Vandesompele

A1 Journal Article in JOURNAL OF THE NATIONAL CANCER INSTITUTE

2006

Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma

Tom Van MaerkenFranki SpelemanJ VERMEULENIrina LambertzSarah De ClercqEls De SmetNurten YigitV COPPENSJan PhilippéAnne De PaepeJean-Christophe MarineJo Vandesompele

A1 Journal Article in CANCER RESEARCH